Modern treatments have the potential to change the lives of people with haemophilia, but are not yet available to everyone who needs them. We want to help improve access to treatment for people with haemophilia, making it fairer and more equal.
One way we are doing this is through our support to donation programmes. Together with Bioverativ we are donating one billion units of clotting factor for humanitarian aid in developing countries over the next ten years. The first 500 million have already been earmarked for the World Federation of Hemophilia’s Humanitarian Aid Program, to help improve the standard of care for people with haemophilia in the developing world.